CC
GPCR icon

Casdin Capital’s Structure Therapeutics GPCR Stock Holding History

Casdin Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$1.02M – 39
2023
Q4 		$1.02M Buy
+25,000
New +$1.43M 0.1% 35

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Casdin Capital's GPCR Position: Q1 2026 in Review

Casdin Capital held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 1,175,000 shares worth $56.6M. The position accounts for 4.29% of the portfolio, ranked #7.

Casdin Capital first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $81.7M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Casdin Capital held 1,175,000 shares of Structure Therapeutics worth $56.6M as of Q1 2026.
  • Casdin Capital left its Structure Therapeutics share count unchanged in Q1 2026.
  • Structure Therapeutics made up 4.29% of Casdin Capital's portfolio in Q1 2026, its #7 holding.
  • Casdin Capital first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Casdin Capital's Structure Therapeutics position peaked at $81.7M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.